157 related articles for article (PubMed ID: 36457288)
1. Aptamer-mediated hollow MnO
Wang Z; Wu C; Liu J; Hu S; Yu J; Yin Q; Tian H; Ding Z; Qi G; Wang L; Hao L
Drug Deliv; 2023 Dec; 30(1):28-39. PubMed ID: 36457288
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle Delivery of MnO
Chang CC; Dinh TK; Lee YA; Wang FN; Sung YC; Yu PL; Chiu SC; Shih YC; Wu CY; Huang YD; Wang J; Lu TT; Wan D; Chen Y
ACS Appl Mater Interfaces; 2020 Oct; 12(40):44407-44419. PubMed ID: 32865389
[TBL] [Abstract][Full Text] [Related]
3. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
[TBL] [Abstract][Full Text] [Related]
4. Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis.
Wu H; Wang C; Sun J; Sun L; Wan J; Wang S; Gu D; Yu C; Yang C; He J; Zhang Z; Lv Y; Wang H; Yao M; Qin W; Wang C; Jin H
ACS Appl Mater Interfaces; 2019 Nov; 11(47):43996-44006. PubMed ID: 31682099
[TBL] [Abstract][Full Text] [Related]
5. Targeted Delivery of Glypican 3 (GPC3) Antibody-Modified MicroRNA (miR let-7b-5p) Polymer Nanoparticles to Sorafenib-Resistant Hepatsocellular Carcinoma Cells.
Zhou S; Ma Y; Liu X; Yu P; Huang N; Song L; Xu R; Huo Z; Zhu T; Tang X
J Biomed Nanotechnol; 2021 Apr; 17(4):677-690. PubMed ID: 35057893
[TBL] [Abstract][Full Text] [Related]
6. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
7. Monodisperse Hollow MnO
Cheng M; Yu Y; Huang W; Fang M; Chen Y; Wang C; Cai W; Zhang S; Wang W; Yan W
ACS Biomater Sci Eng; 2020 Sep; 6(9):4985-4992. PubMed ID: 33455291
[TBL] [Abstract][Full Text] [Related]
8. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma.
Zhao M; Liu Z; Dong L; Zhou H; Yang S; Wu W; Lin J
Int J Nanomedicine; 2018; 13():4433-4443. PubMed ID: 30122918
[TBL] [Abstract][Full Text] [Related]
9. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Wang Z; Zhao K; Zhang Y; Duan X; Zhao Y
Pharm Res; 2019 Aug; 36(10):145. PubMed ID: 31396764
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma.
Feng S; Zhou J; Li Z; Appelman HD; Zhao L; Zhu J; Wang TD
Colloids Surf B Biointerfaces; 2019 Dec; 184():110498. PubMed ID: 31536939
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment-responsive versatile "Trojan horse" theranostic nanoplatform for magnetic resonance imaging-guided multimodal synergistic antitumor treatment.
Huang Q; Pan Y; Wang M; Liu Z; Chen H; Wang J; Zhao Z; Zhang Y
Acta Biomater; 2022 Jul; 147():270-286. PubMed ID: 35595202
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
13. Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.
Hou M; Liu M; Yu H; Kou Y; Jia J; Zhou Q; Zhang F; Zhao D; Zhao T; Li X
Nano Lett; 2024 Jan; 24(4):1284-1293. PubMed ID: 38230643
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment responsive hollow mesoporous Co
Huang J; Huang Y; Xue Z; Zeng S
Biomaterials; 2020 Dec; 262():120346. PubMed ID: 32927232
[TBL] [Abstract][Full Text] [Related]
15. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
16. Fe-MnO
Huang D; Xu D; Chen W; Wu R; Wen Y; Liu A; Lin L; Lin X; Wang X
Biomed Pharmacother; 2023 May; 161():114431. PubMed ID: 36827713
[TBL] [Abstract][Full Text] [Related]
17. Hollow MnO
Yang G; Xu L; Chao Y; Xu J; Sun X; Wu Y; Peng R; Liu Z
Nat Commun; 2017 Oct; 8(1):902. PubMed ID: 29026068
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma.
Xu W; Yang M; Zhang W; Jia W; Zhang H; Zhang Y
Mater Today Bio; 2024 Feb; 24():100902. PubMed ID: 38188646
[TBL] [Abstract][Full Text] [Related]
19. Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles.
Wang H; Sun S; Zhang Y; Wang J; Zhang S; Yao X; Chen L; Gao Z; Xie B
Drug Deliv; 2019 Dec; 26(1):89-97. PubMed ID: 30744448
[TBL] [Abstract][Full Text] [Related]
20. Multi-stimuli responsive hollow MnO
Xu X; Duan J; Liu Y; Kuang Y; Duan J; Liao T; Xu Z; Jiang B; Li C
Acta Biomater; 2021 May; 126():445-462. PubMed ID: 33785453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
